PTSM: Pharmaceutical Technology Sourcing and Management
Air Cargo Community Frankfurt takes steps to make Frankfurt Europe’s largest certified pharmaceutical hub.
In an April 25, 2016 press announcement, Air Cargo Community Frankfurt said Frankfurt is becoming Europe’s largest certified pharmaceutical hub. According to the press announcement, numerous companies are pursuing the IATA CEIV Pharma certification with the common goal of making Frankfurt the largest certified pharmaceutical gateway in Europe.
The Air Cargo Community Frankfurt said they intend to have each step of the process certified to ensure a high degree of reliability and security throughout the process. According to a press announcement, the Community is coordinating special training for the employees of participating companies to ensure the success of the certification process.
The Perishable Center GmbH & Co. Betriebs KG, Frankfurt and Bolloré Logistics Germany GmbH in Frankfurt have successfully completed the IATA CEIV Pharma certification at this time. Beyond that, additional companies are already in the process or are starting the nine-month certification process on location. Among them are:
"We are offering a wide range of services based on the IATA CEIV Pharma-Standards as soon as the certification of these companies has been completed,” said Joachim von Winning, executive director Air Cargo Community Frankfurt. “For instance, more than 95% of the freight handling companies and approximately 85% of those providing apron transportation and loading services at Frankfurt Airport will then be certified.”
In addition to IATA CEIV Pharma Certification, the Air Cargo Community Frankfurt is working with pharmaceutical companies to ensure products and services on locations meet all requirements. The Community is also developing shared products for temperature-controlled transport.
Source: Air Cargo Community Frankfurt
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.